Literature DB >> 8561963

Catecholamine and MHPG plasma levels, platelet MAO activity, and 3H-imipramine binding in heroin and cocaine addicts.

T Macedo1, C A Ribeiro, D Cotrim, P Tavares, M T Morgadinho, M Caramona, M T Vicente, L Rodrigues, M G Cardoso, M L Keating.   

Abstract

This work evaluated in a population of heroin and heroin plus cocaine human addicts: 1. Norepinephrine (NE), epinephrine (Epi) and 3-methoxy-4-hydroxyphenylglycol (MHPG) (the principal metabolite of brain NE) plasma levels; 2. Monoamine oxidase (MAO) activity; and 3. 3H-imipramine specific binding to the amine carrier in platelets. NE plasma levels were significantly lower in the short-term heroin user groups (1-3 and 4-6 yr), a finding not observed in both long-term heroin user ( > 6 yr) and heroin plus cocaine user ( > 6 yr) groups. Epi levels changed in a similar manner, except that a significant increase was noted in heroin plus cocaine abusers. Conversely, dopamine and MHPG plasma levels increased with the duration of heroin use, and even more with cocaine abuse. Platelet MAO activity increased in all groups. Specific 3H-imipramine binding sites showed an increase after 3 yr of heroin abuse and in all heroin plus cocaine addicts. In conclusion, short-term use of heroin decreases NE or Epi release, but with prolonged use, a slow adaptation occurs. In contrast, cocaine inhibits the neuronal Epi uptake, even in a situation of long duration of abuse. Probably the amine levels additionally regulate the amine carrier, resulting in changes that show a different pattern from major depression. These drugs of abuse may also influence directly or indirectly related enzymatic systems.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8561963     DOI: 10.1007/bf02740681

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  33 in total

1.  Monoamine oxidase activity in blood platelets of migraine patients.

Authors:  M M Caramona; M D Cotrim; C F Ribeiro; T Macedo
Journal:  J Neural Transm Suppl       Date:  1990

Review 2.  Drugs of abuse: anatomy, pharmacology and function of reward pathways.

Authors:  G F Koob
Journal:  Trends Pharmacol Sci       Date:  1992-05       Impact factor: 14.819

3.  The effects of phencyclidine on the uptake of 3H-catecholamines by rat striatal and hypothalamic synaptosomes.

Authors:  R E Garey; R G Heath
Journal:  Life Sci       Date:  1976-05-15       Impact factor: 5.037

4.  Age-related changes in 5HT uptake and [3H]imipramine binding sites in rat cerebral cortex.

Authors:  N Brunello; M Riva; A Volterra; G Racagni
Journal:  Eur J Pharmacol       Date:  1985-04-16       Impact factor: 4.432

Review 5.  Origin and distribution of 3-methoxy-4-hydroxyphenylglycol in body fluids.

Authors:  E M DeMet; A E Halaris
Journal:  Biochem Pharmacol       Date:  1979-10-15       Impact factor: 5.858

Review 6.  Catecholamine metabolism: basic aspects and clinical significance.

Authors:  I J Kopin
Journal:  Pharmacol Rev       Date:  1985-12       Impact factor: 25.468

7.  Age alters the observed response of imipramine binding sites to chronic antidepressant treatment in female rats.

Authors:  M A Wilson; E J Roy
Journal:  Eur J Pharmacol       Date:  1984-11-13       Impact factor: 4.432

8.  Naloxone administration releases catecholamines.

Authors:  M Mannelli; M Maggi; M L De Feo; S Cuomo; G Forti; F Moroni; G Giusti
Journal:  N Engl J Med       Date:  1983-03-17       Impact factor: 91.245

9.  High affinity binding of [3H]paroxetine and [3H]imipramine to human platelet membranes.

Authors:  E T Mellerup; P Plenge; M Engelstoft
Journal:  Eur J Pharmacol       Date:  1983-12-23       Impact factor: 4.432

10.  (-)-Deprenyl a selective MAO "B' inhibitor, increases [3H]imipramine binding and decreases beta-adrenergic receptor function.

Authors:  G Zsilla; M L Barbaccia; O Gandolfi; J Knoll; E Costa
Journal:  Eur J Pharmacol       Date:  1983-04-22       Impact factor: 4.432

View more
  9 in total

Review 1.  Treatment of patients with cocaine-induced arrhythmias: bringing the bench to the bedside.

Authors:  Robert S Hoffman
Journal:  Br J Clin Pharmacol       Date:  2010-05       Impact factor: 4.335

Review 2.  Substance use modulates stress reactivity: Behavioral and physiological outcomes.

Authors:  Anne Q Fosnocht; Lisa A Briand
Journal:  Physiol Behav       Date:  2016-02-19

3.  Elevated platelet vesicular monoamine transporter 2 in former heroin addicts maintained on methadone.

Authors:  K Schwartz; I Herman; G Peer; A Weizman; M Rehavi
Journal:  J Neural Transm (Vienna)       Date:  2006-07-20       Impact factor: 3.575

4.  Differences in platelet serotonin transporter sites between African-American tobacco smokers and non-smokers.

Authors:  Ashwin A Patkar; Raman Gopalakrishnan; Wade H Berrettini; Stephen P Weinstein; Michael J Vergare; Frank T Leone
Journal:  Psychopharmacology (Berl)       Date:  2003-02-13       Impact factor: 4.530

5.  Association between platelet MAO activity and lifetime drug use in a longitudinal birth cohort study.

Authors:  Katre Sakala; Kairi Kasearu; Urmeli Katus; Toomas Veidebaum; Jaanus Harro
Journal:  Psychopharmacology (Berl)       Date:  2022-01-10       Impact factor: 4.530

6.  Opioid use affects antioxidant activity and purine metabolism: preliminary results.

Authors:  Paolo Mannelli; Ashwin Patkar; Steve Rozen; Wayne Matson; Ranga Krishnan; Rima Kaddurah-Daouk
Journal:  Hum Psychopharmacol       Date:  2009-12       Impact factor: 1.672

7.  Prenatal Cocaine Disrupts Serotonin Signaling-Dependent Behaviors: Implications for Sex Differences, Early Stress and Prenatal SSRI Exposure.

Authors:  Sarah K Williams; Jean M Lauder; Josephine M Johns
Journal:  Curr Neuropharmacol       Date:  2011-09       Impact factor: 7.363

Review 8.  Elevated Norepinephrine may be a Unifying Etiological Factor in the Abuse of a Broad Range of Substances: Alcohol, Nicotine, Marijuana, Heroin, Cocaine, and Caffeine.

Authors:  Paul J Fitzgerald
Journal:  Subst Abuse       Date:  2013-10-13

9.  Monoamine and genome-wide DNA methylation investigation in behavioral addiction.

Authors:  Yui Asaoka; Moojun Won; Tomonari Morita; Emi Ishikawa; Young-A Lee; Yukiori Goto
Journal:  Sci Rep       Date:  2020-07-16       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.